A new study from the Karolinska Institutet in Sweden has revealed that the diabetes drug Ozempic, which is becoming increasingly popular as a weight loss aid and appetite suppressant, may also have a preventive effect against certain types of cancer. The research specifically found that the semaglutide injection, classified as a glucagon-like peptide-1 (GLP-1) receptor agonist, can reduce the risks of both liver cancer and cirrhosis in individuals with chronic liver disease and type 2 diabetes.

The findings, published in the journal Gut, are considered significant as there are currently no approved medications available to combat the risk of liver cancer and cirrhosis. "Our findings are interesting because there are currently no approved drugs to reduce this risk," explained Axel Wester, the first author of the study. The study observed individuals in Sweden who had both type 2 diabetes and chronic liver disease, and it was discovered that those who were taking Ozempic and similar GLP1 medications over an extended period had a lower risk of developing the two liver diseases.

Hannes Hagström, another author of the study, expressed optimism about the results, stating, "If we get similar results, it would further strengthen the hypothesis that GLP1 agonists can be used to reduce the risk of severe liver disease."

However, alongside the drug's rising popularity, especially within the Hollywood community, concerns of overdoses have also increased, according to America's Poison Centers. It is important to note that the study does not address the issue of overdose in relation to Ozempic.

This study is the latest addition to a growing body of research indicating positive side-effects of Ozempic. Late last year, a study published in The Journal of Clinical Psychiatry suggested that the drug could potentially help in curing alcohol cravings, further highlighting its potential beyond its intended use.

While more research is needed to fully understand the effects of Ozempic, these new findings offer promising insights into its potential as a preventive measure against liver cancer and cirrhosis for individuals with chronic liver disease and type 2 diabetes.